1. Richeldi L et al. N Engl J Med 2014;370:2071–82.
2. Wollin L et al. Eur Respir J 2015;45:1434–45.
3. Wollin L et al. Eur Respir J 2019; doi: 10.1183/13993003.00161–2019.
4. Maher TM et al. Lancet Respir Med 2019;7:771–9.

The INMARK trial was funded by Boehringer Ingelheim. Editorial and formatting assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK during preparation of this poster. The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development and have approved the final version. Boehringer Ingelheim was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. The authors received no direct compensation related to the development of this poster. Eric S White is now an employee of Boehringer Ingelheim Pharmaceuticals, Inc. Moisés Selman has served as a consultant for Boehringer Ingelheim. Toby M Maher reports grants and personal fees from GlaxoSmithKline and UCB, and personal fees from Apellis, Bayer, Biogen Idec, Blade, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galecto, Indalo, Novartis, Respivent, Roche, and Trevi.